No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 320 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Acalabrutinib June 18, 2025 Groom Uses Wedding To Ask Stepdaughters If He Can Adopt Them September 10, 2021 12-Yr-Old Chokes Up When Nurses Surprise Him With Special Song For... October 29, 2019 Quarantined Cruise Ship Passenger Concerned She Won’t Make It Home for... March 11, 2020 Load more HOT NEWS Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... Progress in Treating GI Cancers Through Molecular Testing: The 2021 Advance...
